Clinical trial
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of…
NCT00267202 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00267202 |
|---|---|
| Title | Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma |
| Official title | A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids |
| Lead sponsor | Novartis, Industry |
| Collaborators | Genentech, Inc. Industry Tanox |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Allergic Asthma |
| Intervention type | Drug |
| Interventions | Placebo, Omalizumab, Immunotherapy |
| Enrollment | 275 |
| Start date | Dec 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Dec 20, 2005 |
| Last update posted | Sep 14, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: